• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    HWH International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    9/25/24 5:19:52 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care
    Get the next $HWH alert in real time by email
    false 0001897245 0001897245 2024-09-24 2024-09-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 24, 2024

     

    HWH International Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41254   87-3296100

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    4800 Montgomery Lane, Suite 210 Bethesda, MD   20814
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (301) 971-3955

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   HWH   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On September 24, 2024, HWH International Inc. (the “Company”) entered into two (2) debt conversion agreements with creditors (each an “Agreement,” or collectively, the “Agreements”): (i) Alset International Limited (the Company’s majority stockholder); and (ii) Alset Inc. (which is Alset International Limited’s majority stockholder). Each Agreement converts debt owed by the Company to the respective creditor into shares of the Company’s common stock. The Agreements are substantially the same with the exception of the amount of debt to be converted under each.

     

    Under the terms of their respective agreements, Alset Inc. shall convert $300,000.00 of the Company’s debt into 476,190 shares of the Company’s common stock, and Alset International Limited shall convert $3,501,759.00 of the Company’s debt into 5,558,347 shares of the Company’s common stock. Under the Agreements, the debt conversions shall result in the issuance of newly issued shares of the Company’s common stock. The price at which the debt conversion was fixed was set at $0.63 per share. Cumulatively, the newly issued shares contemplated by the Agreements represent 6,034,537 new shares of the Company’s common stock, constituting an increase to the total issued and outstanding shares of the Company’s common stock of 37.2% over the amount immediately preceding the effectiveness of the Agreements. The shares contemplated by the Agreements are restricted securities under the Securities Act of 1933, and shall be issued in reliance upon the safe harbor provided by Rule 506 of Regulation D.

     

    The Company’s Chairman, Chan Heng Fai, is also the Chairman and Chief Executive Officer of each of Alset Inc. and Alset International Limited., and is the majority stockholder of Alset Inc. Each of our independent directors is also an independent director of Alset Inc., and certain independent directors are also members of the board of Alset International Limited.

     

    The foregoing description is only a summary of the material provisions of the Agreements and is qualified in its entirety by reference to the copy of each Agreement, which are filed as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K and incorporated by reference herein.

     

    Item 3.02 Unregistered Sales of Equity Securities

     

    The disclosures set forth in Item 1.01 above are hereby incorporated into this Item 3.02 by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Debt Conversion Agreement, between HWH International Inc. and Alset Inc., dated September 24, 2024
    10.2   Debt Conversion Agreement, between HWH International Inc. and Alset International Limited, dated September 24, 2024
    104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 25, 2024 HWH INTERNATIONAL INC.
         
      By: /s/ Rongguo Wei
      Name: Rongguo Wei
      Title: Chief Financial Officer

     

     

     

     

    Get the next $HWH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HWH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chan Heng Fai Ambrose bought $585,000 worth of shares (1,300,000 units at $0.45) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    12/26/24 5:15:05 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Director Chan Heng Fai Ambrose bought $3,000,000 worth of shares (4,411,764 units at $0.68) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    11/26/24 7:12:12 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Chan Heng Fai Ambrose bought $3,801,758 worth of shares (6,034,537 units at $0.63) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    9/26/24 9:39:51 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Chan Heng Fai Ambrose

    4 - HWH International Inc. (0001897245) (Reporting)

    1/20/26 4:59:26 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Chan Heng Fai Ambrose was granted 1,000,000 shares, increasing direct ownership by 38,462% to 1,002,600 units (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    12/1/25 5:10:23 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Large owner Chan Heng Fai Ambrose

    4 - HWH International Inc. (0001897245) (Reporting)

    10/7/25 5:00:04 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    SEC Filings

    View All

    SEC Form DEFM14C filed by HWH International Inc.

    DEFM14C - HWH International Inc. (0001897245) (Filer)

    2/17/26 9:00:21 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    SEC Form 144 filed by HWH International Inc.

    144 - HWH International Inc. (0001897245) (Subject)

    2/11/26 7:37:45 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    HWH International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - HWH International Inc. (0001897245) (Filer)

    2/5/26 8:45:59 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HWH International Inc. Announces Reverse Stock Split

    BETHESDA, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced a 1-for-5 reverse stock split of the Company's common stock to become effective at 9:00 a.m. (Eastern Time) on February 24, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on February 24, 2025, under the existing trading symbol "HWH." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 448

    2/20/25 8:50:00 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering

    BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,900, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,412,500 shares of common stock and 1,000,000 pre-funded warrants to purchase 1,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded

    1/7/25 11:18:56 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    HWH International Inc. Announces Closing of Approximately $1.76 Million Public Offering at $0.40 per Share

    BETHESDA, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,875, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,125,000 shares of common stock and 1,250,000 pre-funded warrants to purchase 1,250,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded w

    1/6/25 4:20:00 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Financials

    Live finance-specific insights

    View All

    HWH International Inc. Acquires Café in South Korea, Unveiling Second Hapi Cafe Outlet

    Bethesda, MD, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. ("HWH") (NASDAQ:HWH) proudly announces the acquisition of a café in Seocho-gu, South Korea, marking the launch of its second Hapi Cafe outlet in South Korea. HWH is delighted to reveal its latest acquisition of a café nestled in the heart of Seocho-gu, South Korea. This strategic move signifies HWH's dedication to providing unique and welcoming spaces where people can gather to savor food, coffee, and experiences. These cafes are a significant driver of our Health, Wealth, and Happiness vision to offer delicious and nutritious food and beverages to our customers and provide a platform where we can roll out lifestyle pr

    2/26/24 4:15:00 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/26/24 7:34:11 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/22/24 5:00:10 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by HWH International Inc.

    SC 13G/A - HWH International Inc. (0001897245) (Subject)

    11/14/24 12:40:52 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care